JP2014515367A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515367A5
JP2014515367A5 JP2014511908A JP2014511908A JP2014515367A5 JP 2014515367 A5 JP2014515367 A5 JP 2014515367A5 JP 2014511908 A JP2014511908 A JP 2014511908A JP 2014511908 A JP2014511908 A JP 2014511908A JP 2014515367 A5 JP2014515367 A5 JP 2014515367A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
dengue virus
inactivated dengue
inactivated
bulk preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014511908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/059879 external-priority patent/WO2012160199A1/en
Publication of JP2014515367A publication Critical patent/JP2014515367A/ja
Publication of JP2014515367A5 publication Critical patent/JP2014515367A5/ja
Pending legal-status Critical Current

Links

JP2014511908A 2011-05-26 2012-05-25 不活性化デング熱ウイルスワクチン Pending JP2014515367A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161490205P 2011-05-26 2011-05-26
US61/490,205 2011-05-26
US201161570966P 2011-12-15 2011-12-15
US61/570,966 2011-12-15
PCT/EP2012/059879 WO2012160199A1 (en) 2011-05-26 2012-05-25 Inactivated dengue virus vaccine

Publications (2)

Publication Number Publication Date
JP2014515367A JP2014515367A (ja) 2014-06-30
JP2014515367A5 true JP2014515367A5 (cg-RX-API-DMAC7.html) 2015-06-11

Family

ID=46148894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511908A Pending JP2014515367A (ja) 2011-05-26 2012-05-25 不活性化デング熱ウイルスワクチン

Country Status (16)

Country Link
US (1) US20140112953A1 (cg-RX-API-DMAC7.html)
EP (1) EP2714076A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014515367A (cg-RX-API-DMAC7.html)
KR (1) KR20140033171A (cg-RX-API-DMAC7.html)
CN (2) CN107050445A (cg-RX-API-DMAC7.html)
AU (2) AU2012260807B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030236A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837145A1 (cg-RX-API-DMAC7.html)
CO (1) CO6811814A2 (cg-RX-API-DMAC7.html)
EA (1) EA201391515A1 (cg-RX-API-DMAC7.html)
IL (1) IL229307A0 (cg-RX-API-DMAC7.html)
MX (1) MX349119B (cg-RX-API-DMAC7.html)
PE (1) PE20140646A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502442A1 (cg-RX-API-DMAC7.html)
SG (1) SG194950A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012160199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207936B1 (en) 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
US10765727B2 (en) 2015-09-26 2020-09-08 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BE1024160A9 (fr) * 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN107140625A (zh) * 2017-06-14 2017-09-08 中国海洋大学 一种利用植物油制备石墨烯薄膜的方法
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN111526885A (zh) 2017-11-03 2020-08-11 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
CA3084605A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Method for inactivating zika virus and related methods
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
AU2020403013A1 (en) * 2019-12-11 2022-06-02 Ne1 Inc. Personalized tumor vaccine and use thereof for cancer immunotherapy
US20240076631A2 (en) * 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用
CN115531529A (zh) * 2022-09-16 2022-12-30 大连理工大学 一种冻干保护剂在含铝佐剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.
HUE051878T2 (hu) * 2003-02-10 2021-03-29 Biogen Ma Inc Immunglobulin készítmény és annak elõállítási módszere
EP2811027A1 (en) * 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
DK2144998T3 (en) * 2007-04-06 2017-04-10 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
EP2337847B1 (en) * 2008-09-29 2015-12-02 Cadila Pharmaceuticals Ltd. Vaccine adjuvants
PE20110992A1 (es) * 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
US9005633B2 (en) * 2009-07-17 2015-04-14 The United States Of America As Represented By The Secretary Of The Navy. Psoralen-inactivated viral vaccine and method of preparation
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Similar Documents

Publication Publication Date Title
JP2014515367A5 (cg-RX-API-DMAC7.html)
US11406698B2 (en) Vaccine compositions
JP6147734B2 (ja) 不活化チクングニアウイルス株を含むワクチン組成物
TWI812650B (zh) 包含特別是減毒活重組黃病毒的穩定疫苗組成物以及製備其的製程
CN111447947B (zh) 登革病毒疫苗组合物的制剂
CN103619349A (zh) 灭活登革热病毒疫苗
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
US20110189226A1 (en) Immunization Compositions and Methods
US9834757B2 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2017156511A8 (en) Live attenuated zika virus vaccine
EP3838290A1 (en) Vaccine compositions comprising an attenuated mutant zika virus
EP3481848B1 (en) Genomic sequences encoding for an attenuated mutant zika virus
WO2017109698A1 (en) Immunogenic formulation
US20190054161A1 (en) Inactivated vaccine for chikungunya virus
BR112018000862B1 (pt) Composição de vacina estável, método para produção de antígeno de vírus da zika recombinante e método para preparação de antígeno de virião (vírus) inteiro inativado da zika para formulação de vacina de vírus da zika